Table 2 Mean and SD of primary and secondary outcome measures for continuous ultrasound and placebo ultrasound groups at baseline, after 10 treatment sessions, and after 1 month follow up
Parameter | Continuous US* | Placebo US | P value*** | ||||
|---|---|---|---|---|---|---|---|
Before treatment | After 10 sessions | After 1 month | Before treatment | After 10 sessions | After 1 month | ||
N=24 | N=24 | N=21 | N=24 | N=24 | N=18 | ||
FRI** | 40.8 (14.6) | 23.4 (6.9) | 22.8 (7.8) | 43.9 (16.9) | 31.1 (13.4) | 30.5 (11.9) | .49 |
VAS** | 46.6 (17.7) | 26.6 (13.8) | 27.7 (14.4) | 49 (16) | 30.7 (13.1) | 25.5 (9.9) | .62 |
Flexion ROM (millimeters) | 48.8 (19.4) | 52.4 (18.6) | 52.4 (19.60) | 57.4 (18.9) | 59.8 (17.9) | 57.5 (18.3) | .13 |
Extension ROM (millimeters) | 19.4 (8.2) | 20.12 (8.5) | 21.7 (8.5) | 23.6 (9.6) | 24.1 (9.3) | 24.7 (9.6) | .11 |
Endurance time(in seconds) | 111.5 (33.5) | 128.9 (30.2) | 128.3 (26.2) | 134.2 (27.1) | 140.3 (43.5) | 139.3 (45.8) | .01 |
Median frequency slope of right muscles | |||||||
Illiocostalis lumborum | -.24 (.17) | -.21 (.09) | -.19 (.07) | -.21 (.13) | -.20 (.06) | -.19 (.06) | .56 |
Multifidus | -.26 (.15) | -.26 (.16) | -.24 (.13) | -.30 (.17) | -.25 (.05) | -.24 (.05) | .82 |
Gluteus maximus | -.11 (.13) | -.09 (.10) | -.09 (.10) | -.13 (.13) | -.09 (.09) | -.09 (.1) | .65 |
Biceps femoris | -.12 (.09) | -.12 (.08) | -.09 (.06) | -.11 (.07) | -.12 (.07) | -.09 (.05) | .83 |
Median frequency slope of left muscles | |||||||
Illiocostalis lumborum | -.18 (.11) | -.18 (.11) | -.16 (.09) | -.21 (.12) | -.19 (.07) | -.18 (.08) | .29 |
Multifidus | -.24 (.14) | -.25 (.15) | -.25 (.15) | -.29 (.21) | -.24 (.10) | -.25 (.11) | .31 |
Gluteus Maximus | -.06 (.04) | -.06 (.06) | -.08 (.05) | -.09 (.07) | -.08 (.05) | -.09 (.08) | .11 |